Examining the Latest Therapies and Quality Improvement Strategies for Heart Failure
February 28, 2017 from 1 PM to 2:30 PM ET

Examining the Latest Therapies and Quality Improvement Strategies for Heart Failure

Jointly provided by
Impact Education, LLC    
This activity is supported by educational funding donation provided by Amgen.

This webcast is now available as an on-demand free CE activity at:


Up to 1.5 contact hours available for pharmacists. Pharmacists may upload the record of their completion to CPE Monitor immediately upon completing this activity.

  • Emerging therapies for heart failure (HF)
  • Latest evidence on averting HF-related hospitalizations and/or deaths
  • HF quality improvement in health-system operations and infrastructure
  • Collaborative strategies for HF management
Akshay S. Desai, MD, MPH
Director, Heart Failure Disease Management Program
Advanced Heart Disease Section, Cardiovascular Division
Brigham and Women's Hospital
Associated Professor of Medicine
Harvard Medical School
James Jorgenson, MS, RPh, FASHP
Chief Executive Officer
Board Chair
Visante, Inc.
Jo Ellen Rodgers, PharmD, FCCP, BCPS-AQ
Associate Director, Clinical Fellowship Programs
Clinical Associate Professor
UNC Eshelman School of Pharmacy

This activity is designed to meet the educational needs of health-system pharmacy professionals.


HF is the leading cause of hospitalization among adults >65 years of age in the United States. HF-associated hospitalization represents a noteworthy driver of health care-related costs as well as a surrogate marker for increasing mortality. Rehospitalization, despite improvement in outcomes with medical therapy, is also not uncommon: at least half of patients are readmitted to the hospital within 6 months of discharge. This exemplifies a key area of interest for health care decision makers across all disease states, since reducing readmission rates also reduces costs and indicates an improvement in the quality of care.

As the health care environment continues to evolve, a focus on comprehensive and collaborative disease management will assume a more prominent role within health care organizations. The rise of emerging care models such as the patient-centered medical home (PCMH) and accountable care organizations (ACOs) serve to highlight these changes. This symposium will provide health-system pharmacy professionals with the latest clinical updates and quality improvement strategies for HF to remain at the forefront of the industry and improve patient outcomes while managing overall quality.


At the conclusion of this activity, participants should be able to demonstrate improved ability to:
  • Describe the available efficacy and safety data for emerging therapies in HF, including results from pivotal trials and evidence supporting averted HF-related hospitalizations and/or deaths
  • Discuss available HF quality measures from nationally recognized governing bodies as well as from other health systems across the nation
  • Illustrate opportunities for HF quality improvement in health-system operations and infrastructure and implement measures to facilitate evidence-based treatment and follow-up
  • Characterize the importance of addressing noncardiac comorbidities and overseeing care transitions as they pertain to maintaining therapeutic persistence and improving outcomes
  • Develop collaborative strategies for HF management enlisting the input and support of a multidisciplinary team of health care providers
Integrating Novel Therapies into the Management of Patients with Heart Failure and Reduced Ejection Fraction
Akshay Suvas Desai, MD, MPH
Heart Failure Quality Improvement Strategies for Evidence-Based Treatment and Follow-Up
Jo Ellen Rodgers, PharmD, FCCP, BCPS-AQ
Moderated Faculty Panel Discussion
Faculty Panel
Case Study: Community-Based Cardiology and Health-System Pharmacy Collaboration - Steps for Success
James Jorgenson, MS, RPh, FASHP
Faculty Panel Discussion and Audience Q&A
Faculty Panel

Pharmacist Continuing Education
Accreditation Statement
Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
MER designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - 0816-9999-16-090-L01-P

This activity is certified as Knowledge-based CPE.

Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
There is no fee for this educational activity.

If you have any questions, please call (215) 619-8812 or email info@impactedu.net.